Objective:
The framework partnership will support individual troop readiness and total force health protection by developing technologies and products to rapidly identify and respond to biological threats (including natural and genetically modified organism), chemical hazards and attacks, toxins as well as countermeasures regarding radio-nuclear and nuclear threats. Funded actions also focus on the research and development of vaccines and drugs and other antibiological substances (e.g., bacteriophages) against biological agents that may affect a sizable number of the military and/or be used on the battlefield. A subset of the funded actions specifically supports solutions to be used by personnel with minimal medical training, deployable laboratory capabilities even in the low-resource environments typical of many military operations.
The objective of proposals under this call is to update and/or develop medical countermeasures (MCMs) for the armed forces of EU and – wherever applicable - related civil/health protection to respond to the continuously changing and novel health threats posed by CBRN. It thus aims at developing shared capabilities for EU armed forces against CBRN crises, and to treat exposure, pathologies or injuries of significant impact.
This framework partnership will contribute to responding more efficiently to conflicts, crises, or isolated events involving CBRN situations.
Scope:Scope
To master the evolving threats, the Commission intends to establish a stable and structured partnership with legal entities grouped in a consortium which commit themselves to:
Framework partners should focus on innovation, research and development of medical countermeasures against CBRN threats as well as their integration into EU and Member States and Norway health sector, civil protection mechanism and military forces.
Partners may also provide for analysis of the relevance and feasibility of novel MCMs and related technology, further and/or continuous mapping of CBRN MCM capacities across EU, as well as options for ensuring EU’s access and availability of MCMs.
MCMs may include clinical testing capabilities or methods, any medicines or medical devices that are aimed at combating CBRN threats. This extends both to countermeasures that prevent or treat the threat. For MCMs to be updated, available and able to respond, this entails a large scope covering innovation, research, development and analysis.
Types of activities that can be funded
This partnership will be set up through an FPA, which will enable the completion of a multiannual action plan within the context of the agreement.
Applicants are invited to:
The consortia responding to the call may include military medical commands, research institutes, universities, RTOs, industry, SMEs as well as other organisations that can play a role in the realisation of defence medical countermeasures. The FPA will specify the objectives, the nature of the actions planned, and the procedure for awarding specific grants.
The FPA is expected to contribute to the following outcomes:
Specific grants implemented under the FPA must be in line with the proposed Action Plan and may cover one or more of the activities as referred in article 10(3) of the EDF Regulation.
Types of activities (art 10(3) EDF Regulation) | Eligible for a Research Action? | Eligible for a Development Action? | |
(a) | Activities that aim to create, underpin and improve knowledge, products and technologies, including disruptive technologies, which can achieve significant effects in the area of defence (generating knowledge) | Yes | No |
(b) | Activities that aim to increase interoperability and resilience, including secured production and exchange of data, to master critical defence technologies, to strengthen the security of supply or to enable the effective exploitation of results for defence products and technologies (integrating knowledge) | Yes | Yes |
(c) | Studies, such as feasibility studies to explore the feasibility of new or upgraded products, technologies, processes, services and solutions | Yes | Yes |
(d) | Design of a defence product, tangible or intangible component or technology as well as the definition of the technical specifications on which such a design has been developed, including any partial test for risk reduction in an industrial or representative environment | Yes | Yes |
(e) | System prototyping [1] of a defence product, tangible or intangible component or technology | No | Yes |
(f) | Testing of a defence product, tangible or intangible component or technology | No | Yes |
(g) | Qualification [2] of a defence product, tangible or intangible component or technology | No | Yes |
(h) | Certification [3]of a defence product, tangible or intangible component or technology | No | Yes |
(i) | Development of technologies or assets increasing efficiency across the life cycle of defence products and technologies | No | Yes |
Innovative disruptive technologies, like MCMs that limit the development of resistance (e.g., broad-spectrum or highly specific and individualized MCMs), and platforms for local production of MCMs on-demand, may also be covered.
Functional requirements
Proposals for the FPA must provide for an Action Plan that should cover, but should not limit to, the following areas:
(1) Broad scientific approaches to address general needs
(2) Targeted R&D activities that address specific needs
(3) High-risk activities with potential pivotal outcomes
Proposals for FPAs should expand and strengthen the supply chain, aiming for the development of key enabling technologies while improving notions of control of medical countermeasures.
Proposals for FPAs should also develop an IP strategy to protect innovations in the field of medical countermeasures and to provide information about the IPRs that are open to licensing.
Proposals for FPAs should also cover: (i) the collaboration with other initiatives or programmes at regional, national, EU or NATO level and (ii) any additional support they may receive in their activities from relevant national, or regional programmes and initiatives. They should also contribute to spreading excellence across Europe.
Expected Impact:The Commission expects the partnership to design and implement relevant, quality and impactful activities that fit the objectives and priorities defined in the call. The action plan should clearly demonstrate the organisation's capacity to generate concrete impacts.
Applicants are invited to:
In terms of results, the Commission expects the framework partnership to:
Even if the main objective of the project is to contribute to the armed forces, its results can also be of interest for the civilian sector.
[1]‘System prototype’ means a model of a product or technology that can demonstrate performance in an operational environment.
[2]‘Qualification’ means the entire process of demonstrating that the design of the product, component or technology meets the specified requirements, providing objective evidence by which particular requirements of a design are demonstrated to have been met.
[3]‘Certification’ means the process by which a national authority certifies that the product, component or technology complies with the applicable regulations.